FILE PHOTO: The Teva Pharmaceutical Industries logo is seen during a press conference by its CEO, Kare Schultz, to discuss the company's outlook for 2019 in Tel Aviv, Israel, February 19, 2019. REUTERS / Amir Cohen
Teva Pharmaceutical Industries Ltd received Friday approval from the US Food and Drug Administration to market its generic nasal spray for overdose of opiates, the health regulator said.
This is the first approval for a generic naloxone nasal spray for use in a community by individuals without medical training, the FDA said in a statement.
Nearly 400,000 people died of an opiate overdose from 1999 to 2017, the regulator said, citing data from the Centers for Disease Control and Prevention.
The FDA tentatively approved Teva generic naloxone nasal spray in June of last year.
Report from Ankit Ajmera in Bengaluru; Editing by Chizu Nomiyama